Cancer immunotherapy, particularly immune checkpoint blockade (ICB), has transformed the treatment of advanced cancers, notably melanoma. However, many melanoma patients show limited responses or suffer from immune-related side effects. Therapeutic cancer vaccines aim to stimulate T cells to strengthen antitumor immunity but often lack the immunogenicity needed to effectively activate cytotoxic T lymphocytes (CTLs).

Addressing these limitations, researchers from the University of Michigan, Donghua University, and Shanghai University have developed an innovative approach called Proteolysis-Targeting Vaccines (PROTAVs). Designed to enhance the efficacy of ICB in treating melanoma and potentially other cancers, PROTAVs build on the principles of Proteolysis-Targeting Chimeras (PROTACs), which have shown success in targeting endogenous proteins for degradation in other therapeutic areas.

PROTAVs enhance tumor antigen processing and presentation within antigen-presenting cells (APCs), aiming to elicit strong CD8+ T cell responses. This mechanism significantly boosts ICB efficacy and offers a promising new platform for combination immunotherapy. (Fig. 1)

Fig. 1: Mechanism of action of proteolysis-targeting vaccine (PROTAVs)

Mechanism of Action of PROTAVs

PROTAVs are modular molecular conjugates consisting of three key components:

  1. Tumor-Associated Antigen (TAA) or Peptide: The antigenic part that is recognized by the immune system.
  2. E3 Ligase-Binding Ligand: Facilitates the ubiquitination process.
  3. Linker: Connects the antigen and the E3 ligand.

In APCs, the E3 ligand promotes ubiquitination of the antigen, leading to proteasomal degradation and subsequent cross-presentation of antigen fragments on MHC class I molecules. This cross-presentation enhances CD8+ T cell activation, facilitating a stronger and more targeted immune response against tumor cells expressing the corresponding antigens.

How the PROTAV Vaccine Works

The PROTAV platform is designed to be modular and adaptable to various antigens. In the case of melanoma, researchers developed a PROTAV using a tandem peptide of trivalent melanoma-associated antigens. This PROTAV is co-delivered with bivalent immunostimulant adjuvants using lipid nanoparticles (LNPs). The key steps in the vaccine’s function are:

  1. Co-Delivery: PROTAV and adjuvants are delivered to APCs via LNPs.
  2. Enhanced Antigen Processing: The E3 ligand promotes antigen ubiquitination and degradation.
  3. Improved Antigen Presentation: Processed antigens are presented on MHC class I molecules.
  4. CD8+ T Cell Activation: Enhanced activation of melanoma-specific CD8+ T cells.
  5. Tumor Microenvironment Modulation: When combined with ICB, the immunosuppressive tumor microenvironment is ameliorated.

Major Findings of the Study

The study demonstrated several significant findings:

  1. Linker Optimization: PROTAVs with a tetrameric ethylene glycol (EG4) linker consistently elicited the highest T cell responses.
  2. Enhanced Antigen Processing: PROTAV-OVA showed increased antigen degradation and ubiquitination in dendritic cells (DCs) compared to unmodified chicken ovalbumin (OVA).
  3. Improved Antigen Presentation: PROTAVs enhanced presentation of the murine MHC-I-restricted minimal peptide epitope (SIINFEKL, OVA257–264) on DCs both in vitro and in vivo.
  4. Potent T Cell Responses: Melanoma PROTAVs elicited stronger antigen-specific CD8+ T cell responses compared to unmodified peptide vaccines.
  5. Tumor Microenvironment Modulation: PROTAV-TgT (trivalent antigenic fusion peptide), especially when combined with anti-PD-1 antibodies, promoted tumor infiltration of antitumor T cells and reduced immunosuppression in the tumor microenvironment.
  6. Enhanced Therapeutic Efficacy: In syngeneic melanoma mouse models, PROTAV combined with ICB significantly increased tumor complete regression rates, achieving 100% eradication of large Braf^V600E melanoma without recurrence.

Differences Between PROTAVs and Traditional Tumor-Associated Antigen Vaccines

The following table summarizes the primary differences, highlighting the unique advantages of PROTAVs over traditional peptide tumor antigen vaccines.

AspectPROTAVs (Proteolysis-Targeting Vaccines)Traditional Peptide Tumor Antigen Vaccines
Mechanism of ActionFacilitates antigen proteolytic processing and cross-presentation in APCs by promoting rapid ubiquitination and degradation of antigens.Relies on natural antigen processing pathways without specifically targeting proteolysis.
StructureModular conjugates consisting of a protein/peptide antigen, an E3 ligase-binding ligand, and a linker.Typically consists of just the peptide antigen without additional conjugates.
Antigen ProcessingEnhances antigen processing and presentation by targeting antigens for degradation by the proteasome.Depends on the body’s natural pathways for processing and presenting antigens on MHC-I molecules.
T Cell ResponsesDesigned to potentiate stronger CD8+ T cell responses, with studies showing up to a 3-fold increase in antigen-specific CD8+ T cell responses compared to unmodified vaccines.May produce varying levels of T cell activation, often limited by the immunogenicity of the peptide itself.
Antigen PresentationPromotes antigen cross-presentation to T cells, enhancing the level of antigen presentation on APCs.Relies on natural antigen presentation processes without specific enhancement.
UbiquitinationFacilitates rapid ubiquitination of antigens in APCs, promoting their processing.Does not specifically target ubiquitination pathways.
Combination Therapy PotentialShown to synergize well with immune checkpoint blockade (ICB), enhancing tumor regression rates.May have limited synergy with ICB due to suboptimal T cell responses.
Tumor Microenvironment ModulationDemonstrated ability to reduce immunosuppression in the tumor microenvironment when combined with ICB.May have limited impact on the tumor microenvironment.
CustomizationHighly modular design allows for easy adaptation to different antigens and E3 ligands.Less flexible in design and modification.
Adjuvant UseFrequently co-delivered with potent adjuvants (e.g., cGAS, TLR9 agonists) to boost immunogenicity.May or may not require adjuvants; some traditional vaccines require additional adjuvants to enhance immune response.
Development SpeedCan be rapidly designed and synthesized due to modular structure.Typically requires longer development time, especially when generating new antigens.

Future Applications of PROTAVs

The success of PROTAVs in melanoma models opens up several potential future applications:

  1. Broader Cancer Immunotherapy: The modular nature of PROTAVs allows for adaptation to various tumor antigens, potentially extending their use to other cancer types.
  2. Combination Therapies: The synergistic effect observed with ICB suggests PROTAVs could be valuable in combination immunotherapy strategies.
  3. Personalized Cancer Vaccines: The platform could be adapted to create personalized vaccines targeting patient-specific neoantigens.
  4. Improved Vaccine Design: Insights gained from PROTAV development could inform the design of more effective cancer vaccines in general.
  5. Non-Cancer Applications: The principles of enhanced antigen processing and presentation could potentially be applied to vaccines for infectious diseases or autoimmune disorders.

In conclusion, PROTAVs represent a promising advancement in cancer immunotherapy, offering a novel approach to enhance antigen-specific T cell responses and improve the efficacy of immune checkpoint blockade. While further research and clinical trials are needed to fully validate their potential in humans, the initial results in melanoma models are highly encouraging and warrant continued investigation into this innovative vaccine platform.

In Vitro and Cell-Based Assays Used in the Discovery and Development of PROTAVs

The following in vitro and cell-based assays are utilized in the discovery and development of PROTAVs:

Reference

Wang, Q., Su, T., Cheng, F., et al. (2024). Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma. bioRxiv.

Related Links

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories